Cargando…
Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma
BACKGROUND: Cardiovascular toxicity is a notorious complication of doxorubicin (DXR) therapy for diffuse large B-cell lymphoma (DLBCL). Although surveillance of well-known biological markers for cardiovascular disease (CVD) as NTproBNP and Troponins may be helpful, there are no established markers t...
Autores principales: | Mörth, Charlott, Sabaa, Amal Abu, Freyhult, Eva, Christersson, Christina, Hashemi, Jamileh, Hashemi, Nashmil, Kamali-Moghaddam, Masood, Molin, Daniel, Höglund, Martin, Eriksson, Anna, Enblad, Gunilla |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856776/ https://www.ncbi.nlm.nih.gov/pubmed/33536059 http://dx.doi.org/10.1186/s40959-021-00092-0 |
Ejemplares similares
-
P045: Plasma proteome profiling of cardiotoxicity in patients with Hodgkin lymphoma
por: Ulfstedt, Johan Mattsson, et al.
Publicado: (2022) -
Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
por: Mörth, Charlott, et al.
Publicado: (2018) -
Immune-Proteome Profiling in Classical Hodgkin Lymphoma Tumor Diagnostic Tissue
por: Gholiha, Alex Reza, et al.
Publicado: (2021) -
Age is the most important predictor of survival in diffuse large B‐cell lymphoma patients achieving event‐free survival at 24 months: a Swedish population‐based study
por: Abu Sabaa, Amal, et al.
Publicado: (2021) -
Checkpoint CD47 expression in classical Hodgkin lymphoma
por: Gholiha, Alex Reza, et al.
Publicado: (2022)